*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 1, 2015 (the "**Prospectus**") issued by 3SBio Inc. (the "**Company**"). The Company makes this announcement pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) (the "**Stabilizing Rules**"). This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.*

*This announcement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States except pursuant to Rule 144A or an exemption from registration requirements under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"). The Offer Shares may be offered, sold or delivered outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. There will not and is not currently intended to be any public offering of securities in the United States.*

3SBIO INC.

三生制药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

STABILIZATION ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on July 4, 2015, being the 30th day after the last day of closing of the application lists under the Hong Kong Public Offering. The stabilization actions undertaken during the stabilization period were:

(1) over-allocations of an aggregate of 90,915,000 Shares (the "**Over-allotment Shares**") in the International Placing, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and

(2) the full exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of themselves and the International Underwriters, on June 24, 2015 in respect of the Over-allotment Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at the Offer Price of HK$9.10 per Share.

The Company makes this announcement pursuant to Section 9(2) of the Stabilizing Rules and announces that the stabilization period in connection with the Global Offering ended on July 4, 2015, being the 30th day after the last day of closing of the application lists under the Hong Kong Public Offering.

The stabilization actions undertaken during the stabilization period were:

(1) over-allocations of an aggregate of 90,915,000 Shares in the International Placing, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option); and

(2) the full exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of themselves and the International Underwriters, on June 24, 2015 in respect of the Over-allotment Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). The Over-allotment Shares were allotted and issued by the Company at HK$9.10 per Share. Details of the exercise of the Over-allotment Option are more particularly described in the announcement of the Company dated June 24, 2015.

By Order of the Board
3SBio Inc.
Mr. LOU Jing
Chairman

Hong Kong, July 5, 2015

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive Directors, Mr. LIU Dong and Mr. LV Dong as non-executive Directors, and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive Directors.